BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, March 28, 2024
Home
»
Newsletters
» BioWorld
BioWorld
May 26, 2005
View Archived Issues
Earlier-Stage Deals Demand 'Creative' Structuring Efforts
Read More
House Passes Stem Cell Bill; Bush Veto Looms On Horizon
Read More
Cylene Brings In $26M To Further Lead Cancer Drug
Read More
InterMune Finds Buyer For Amphotec In Three Rivers
Read More
Other News To Note
Read More
Encysive Submits Thelin NDA In PAH, Seeks Accelerated Review
Encysive Pharmaceuticals Inc. set its lead drug candidate, Thelin (sitaxsentan), on the pathway toward approval for pulmonary arterial hypertension by filing a new drug application with the FDA. (BioWorld Today)
Read More